Skip to main content

Table 1 ACR response rates and NNT at Week 24 among the overall population

From: Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis

Treatment ACR20 ACR50 ACR70
Response rate
(95% CrI)
NNT
(95% CrI)
Response rate
(95% CrI)
NNT
(95% CrI)
Response rate
(95% CrI)
NNT
(95% CrI)
Placebo 17.0% (15.4%, 18.7%) 7.0% (5.9%, 8.2%) 2.5% (1.9%, 3.3%)
Adalimumab 61.2% (47.8%, 73.6%) 2.3 (1.8, 3.2) 42.8% (27.0%, 62.5%) 2.8 (1.8, 4.9) 40.8% (15.9%, 82.2%) 2.6 (1.3, 7.4)
Apremilast 33.4% (27.1%, 40.4%) 6.1 (4.4, 9.5) 15.5% (10.9%, 21.8%) 11.8 (7.0, 23.5) 5.0% (2.7%, 9.1%) 40.3 (15.8, 222.7)
Certolizumab pegol 50.2% (38.6%, 62.3%) 3.0 (2.2, 4.6) 27.9% (18.0%, 41.8%) 4.8 (2.9, 8.9) 16.7% (7.9%, 35.9%) 7.0 (3.0, 17.8)
Etanercept 50.1% (35.2%, 65.5%) 3.0 (2.1, 5.4) 46.6% (26.6%, 71.2%) 2.5 (1.6, 5.1) 9.1% (2.7%, 32.6%) 15.2 (3.3, 318.5)
Golimumab 61.6% (45.9%, 76.3%) 2.2 (1.7, 3.4) 39.8% (22.0%, 64.7%) 3.1 (1.7, 6.6) 27.4% (9.2%, 71.8%) 4.0 (1.4, 14.6)
Infliximab 56.2% (39.9%, 72.2%) 2.6 (1.8, 4.3) 57.1% (32.7%, 82.5%) 2.0 (1.3, 3.9) 34.2% (12.1%, 77.9%) 3.2 (1.3, 10.3)
Secukinumab 150 mg 51.1% (414%, 61.0%) 2.9 (2.3, 4.0) 33.8% (23.5%, 46.8%) 3.7 (2.5, 6.0) 27.3% (13.4%, 53.1%) 4.0 (2.0, 9.0)
Secukinumab 300 mg 55.2% (41.0%, 68.8%) 2.6 (1.9, 4.1) 34.0% (20.6%, 51.0%) 3.7 (2.3, 7.2) 27.0% (11.3%, 55.7%) 4.1 (1.9, 11.1)
Ustekinumab 45 mg 35.4% (27.5%, 44.4%) 5.4 (3.7, 9.2) 19.9% (13.0%, 29.9%) 7.7 (4.4, 15.8) 10.2% (4.8%, 21.9%) 13.0 (5.2, 39.7)
Ustekinumab 90 mg 39.9% (31.5%, 49.1%) 4.4 (3.2, 6.7) 23.5% (15.6%, 34.3%) 6.1 (3.7, 11.1) 12.1% (5.9%, 25.2%) 10.4 (4.4, 27.8)
  1. CrI credible interval, NNT number needed to treat